Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.

Antimicrobial agents and chemotherapy - 1 Dec 2011

Driscoll Timothy A, Yu Lolie C, Frangoul Haydar, Krance Robert A, Nemecek Eneida, Blumer Jeffrey, Arrieta Antonio, Graham Michael L, Bradfield Scott M, Baruch Alice, Liu Ping

Abstract excerpt

Voriconazole pharmacokinetics are not well characterized in children despite prior studies. To assess the appropriate pediatric dosing, a study was conducted in 40 immunocompromised children aged 2 to <12 years to evaluate the pharmacokinetics and safety of voriconazole following intravenous (IV)-to-oral (PO) switch regimens based on a previous population pharmacokinetic modeling: 7 mg/kg IV every 12 h (q12h) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antifungal Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Immunocompromised Host

Share to Infusions, Intravenous

Share to Liver Function Tests

Share to Triazoles

Share to Voriconazole

Source

Open in PubMed Open full text

Identifiers

PMID: 21968355
DOI: 10.1128/AAC.00531-11
PMCID: PMC3232783

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.PMID 21968355Read ↗

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.Semantic proximity Read ↗

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.Semantic proximity Read ↗

Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Semantic proximity Read ↗

Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects.Semantic proximity Read ↗

Model-Oriented Dose Optimization of Voriconazole in Critically Ill Children.Semantic proximity Read ↗

Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Semantic proximity Read ↗

Population Pharmacokinetics and Factors Influencing Trough Concentration of Voriconazole in Children with Hematological MalignanciesSemantic proximity Read ↗

Possibly Appropriate Maintenance dose of Voriconazole in pediatric patients: a single center observational studySemantic proximity Read ↗

Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.Semantic proximity Read ↗

Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation PatientsSemantic proximity Read ↗

CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.Semantic proximity Read ↗

Time-varying voriconazole clearance during extracorporeal membrane oxygenation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.